APA (7th ed.) Citation

Twelves, C., Scheithauer, W., McKendrick, J., Seitz, J., Van Hazel, G., Wong, A., . . . Cassidy, J. (2012). Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: Final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Annals of Oncology, 23(5), 1190. https://doi.org/10.1093/annonc/mdr366

Chicago Style (17th ed.) Citation

Twelves, C., W. Scheithauer, J. McKendrick, J.-F Seitz, G. Van Hazel, A. Wong, E. Díaz-Rubio, F. Gilberg, and J. Cassidy. "Capecitabine Versus 5-fluorouracil/folinic Acid as Adjuvant Therapy for Stage III Colon Cancer: Final Results from the X-ACT Trial with Analysis by Age and Preliminary Evidence of a Pharmacodynamic Marker of Efficacy." Annals of Oncology 23, no. 5 (2012): 1190. https://doi.org/10.1093/annonc/mdr366.

MLA (9th ed.) Citation

Twelves, C., et al. "Capecitabine Versus 5-fluorouracil/folinic Acid as Adjuvant Therapy for Stage III Colon Cancer: Final Results from the X-ACT Trial with Analysis by Age and Preliminary Evidence of a Pharmacodynamic Marker of Efficacy." Annals of Oncology, vol. 23, no. 5, 2012, p. 1190, https://doi.org/10.1093/annonc/mdr366.